drugset / Trial / NCT06621329
Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache
Phase 2/3
Recruiting
40 enrolled
University of California, Davis
Agnes Marshall Walker Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.
Timeline
- Start
- 2024-10-17
- Primary completion
- 2026-07
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 0.75 % | Intranasal |
| Subject | Dexamethasone | Small molecule | 1 mg | Intranasal |